Table 1.
Characteristics of Participants and Duration of Follow-up
| Characteristic | TIV (n = 69) | Placebo (n = 46) |
|---|---|---|
| Age group, No. (%) | ||
| 6–8 years | 19 (28) | 16 (35) |
| 9–11 years | 41 (59) | 27 (59) |
| 12–15 years | 9 (13) | 3 (7) |
| Female sex, No. (%) | 30 (43) | 23 (50) |
| Median duration of follow-up, days | 272 | 272 |
| Mean no. of individuals per household | 3.7 | 3.6 |
Abbreviation: TIV, trivalent inactivated influenza vaccine.